IP Library › Granted Patent US 9,505,833
Granted Patent B2
US 9,505,833 · App. 14/078,181 · Granted Nov 29, 2016

Human antibodies that bind human TNF-alpha and methods of preparing the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,505,833
App. No.
14/078,181
Granted
Nov 29, 2016
Kind
B2
Abstract

Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MOO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.

Claims (19)

1. A composition comprising adalimumab and methylglyoxal (MGO)-modified forms of adalimumab, wherein said composition was expressed in Chinese Hamster Ovary (CHO) cells cultured in chemically defined media (CDM), wherein said MGO-modified forms of adalimumab comprise a MGO-modified arginine amino acid at one or more of positions 30 (R30) of SEQ ID NO. 1, 93 (R93) of SEQ ID NO. 1, 108 (R108) of SEQ ID NO. 1, 16 (R16) of SEQ ID NO. 2, 259 (R259) of SEQ ID NO. 2, 359 (R359) of SEQ ID NO. 2, and 420 (R420) of SEQ ID NO. 2, and wherein said composition was purified by ion exchange chromatography such that said MGO-modified forms of adalimumab in said composition comprise less than about 1% of the total amount of adalimumab and MGO-modified forms of adalimumab.

2. The composition of claim 1 , wherein said MGO-modified arginine amino acid is at position 30 (R30) of SEQ ID NO. 1.

3. The composition of claim 1 , wherein said MGO-modified arginine amino acid is at position 93 (R93) of SEQ ID NO. 1.

4. The composition of claim 1 , wherein said MGO-modified arginine amino acid is at position 108 (R108) of SEQ ID NO. 1.

5. The composition of claim 1 , wherein said MGO-modified arginine amino acid is at position 16 (R16) of SEQ ID NO. 2.

6. The composition of claim 1 , wherein said MOO-modified arginine amino acid is at position 259 (R259) of SEQ ID NO. 2.

7. The composition of claim 1 , wherein said MGO-modified arginine amino acid is at position 359 (R359) of SEQ ID NO. 2.

8. The composition of claim 1 , wherein said MGO-modified arginine amino acid is at position 420 (R420) of SEQ ID NO. 2.

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a composition according to claim 1 .

10. The pharmaceutical composition of claim 9 , wherein said MOO-modified arginine amino acid is at position 30 (R30) of SEQ ID NO. 1.

11. The composition of claim 1 , wherein said adalimumab dissociates from human TNF-alpha with a K off rate constant of 1×10 −3 s −1 or less, as determined by surface plasmon resonance.

12. The composition of claim 1 , wherein said MGO-modified forms of adalimumab exhibit decreased binding affinity to human TNF-alpha as compared to the binding affinity exhibited by unmodified adalimumab, as measured by surface plasmon resonance.

13. The composition of claim 12 , wherein said MGO-modified forms of adalimumab exhibit a binding affinity to human TNF-alpha at least about three times less than the binding affinity exhibited by unmodified adalimumab, as measured by surface plasmon resonance.

14. The composition of claim 13 , wherein said MGO-modified arginine amino acid is at position 30 (R30) of SEQ ID NO. 1.

15. A composition comprising adalimumab and methylglyoxal (MGO)-modified forms of adalimumab, wherein said composition was expressed in Chinese Hamster Ovary (CHO) cells cultured in chemically defined media (CDM), wherein said MGO-modified forms of adalimumab comprise a hydroxylimidine, hydroimidazolone, or combinations thereof at one or more of positions 30 (R30) of SEQ ID NO. 1, 93 (R93) of SEQ ID NO. 1, 108 (R108) of SEQ ID NO. 1, 16 (R16) of SEQ ID NO. 2, 259 (R259) of SEQ ID NO. 2, 359 (R359) of SEQ ID NO. 2, and 420 (R420) of SEQ ID NO. 2, and wherein said composition was purified by ion exchange chromatography such that said MGO-modified forms of adalimumab in said composition comprise less than about 1% of the total amount of adalimumab and MGO-modified forms of adalimumab.

16. The composition of claim 15 , wherein said MGO-modified forms of adalimumab comprise a hydroxylimidine at one or more of positions 30 (R30) of SEQ ID NO. 1, 93 (R93) of SEQ ID NO. 1, 108 (R108) of SEQ ID NO. 1, 16 (R16) of SEQ ID NO. 2, 259 (R259) of SEQ ID NO. 2, 359 (R359) of SEQ ID NO. 2, and 420 (R420) of SEQ ID NO. 2.

17. The composition of claim 16 , wherein said hydroxylimidine is at position 30 (R30) of SEQ ID NO. 1.

18. The composition of claim 15 , wherein said MGO-modified forms of adalimumab, comprise a hydroimidazolone at one or more of positions 30 (R30) of SEQ ID NO. 1, 93 (R93) of SEQ ID NO. 1, 108 (R108) of SEQ ID NO. 1, 16 (R16) of SEQ ID NO. 2, 259 (R259) of SEQ ID NO. 2, 359 (R359) of SEQ ID NO. 2, and 420 (R420) of SEQ ID NO. 2.

19. The composition of claim 18 , wherein said hydroimidazolone is at position 30 (R30) of SEQ ID NO. 1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2015
From: CHUMSAE, CHRIS M
To: ABBVIE INC.
Reel/Frame 036478/0746 →